PR Newswire BiotechOriginal article
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001
AVR-001Positive
AI Analysis
Summary
Avere Therapeutics announced a $500 million private placement to support development of AVR-001, a once-weekly oral IL-23 therapy, with combined financing expected to fund operations into 2029.
Financial Highlights
Guidance
funded into 2029
Importance:6/10
Sentiment:
0.60
private placementfinancingonce-weekly oral therapyIL-23
Related Companies
Read the original article
Published by PR Newswire Biotech on August 10, 2026 11:00 AM